Profile: Amphastar Pharmaceuticals Inc (AMPH.O)
20 Aug 2019
Amphastar Pharmaceuticals, Inc., incorporated on May 19, 2004, is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.
Finished Pharmaceutical Product Segment
As of December 31, 2016, the Company manufactured and sold 19 products in its finished pharmaceutical product segment. The Company's marketed products include Enoxaparin, which is used as an anticoagulant; Cortrosyn, which is a lyophilized powder that is indicated for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, which is a bovine-sourced hyaluronidase injection and is used as an adjuvant in subcutaneous fluid administration; Lidocaine jelly, which is a local anesthetic product used primarily for urological procedures; Lidocaine topical solution, which is used as a local anesthetic for various procedures; Phytonadione injection, which is Vitamin K that is used for newborn babies; emergency syringe products, which include critical care drugs, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, naloxone and sodium bicarbonate, which are provided in pre-filled syringes and are designed for emergency use in hospital settings; Lorazepam injection, which is a sedative used prior to surgery and medical procedures; Ketorolac, which is used for acute pain management, usually in a postoperative setting, and Procainamide, which is indicated for the treatment of documented ventricular arrhythmias. The Company's Primatene Mist, is an over-the-counter epinephrine inhalation product candidate, which can be used for the temporary relief of mild symptoms of intermittent asthma.
The Company manufactures and sells insulin API. The Company manufactures and sells two API products, recombinant human insulin (RHI), API and porcine insulin API.
The Company competes with Pfizer, Inc., Sanofi S.A., Sagent Pharmaceuticals, Inc., Akorn, Inc., Sandoz Inc., Mylan Inc., Fresenius Kabi USA and Teva Pharmaceutical Industries Ltd.
Amphastar Pharmaceuticals Inc
11570 6th St
RANCHO CUCAMONGA CA 91730-6025